TKNO Q2 2021 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena

TKNOAlpha Teknova, Inc.

$135M

Q2 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$8M+37.5% YoY

Gross Profit

$3M40.3% margin

Operating Income

-$3M-30.4% margin

Net Income

-$2M-27.1% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

-8.4%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$8M

Stock-Based Comp.

$302,000

Balance Sheet

Total Assets

$173M

Total Liabilities

$24M

Stockholders' Equity

$149M

Cash & Equivalents

$108M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$6M	+37.5%
Gross Profit	$3M	$3M	-3.3%
Operating Income	-$3M	$704,000	-458.8%
Net Income	-$2M	$512,000	-539.5%

Revenue Segments

Lab Essentials

$6M78%

Clinical Solutions

$2M19%

Other Product

$227,0003%

Sample Transport

$37,0000%

Geographic Segments

UNITED STATES

$8M97%

Non Us

$252,0003%